A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

• Asıl Yazarlar: Shoji Nagao (Yazar), Ai Kogiku (Yazar), Kazuhiro Suzuki (Yazar), Takashi Shibutani (Yazar), Kasumi Yamamoto (Yazar), Tomoatsu Jimi (Yazar), Miho Kitai (Yazar), Takaya Shiozaki (Yazar), Kazuko Matsuoka (Yazar), Satoshi Yamaguchi (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: BMC, 2020-02-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Introduction Bevacizumab and gemcitabine are key drugs for treating recurrent epithelial ovarian cancer. However, information about the combination of bevacizumab and gemcitabine is insufficient. We conducted a phase II study to assess the feasibility, clinical activity, and toxicity of thi...